XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues:      
Total revenues $ 27,281 $ 27,305 $ 24,689
Costs and expenses:      
Cost of goods sold 5,657 6,601 4,572
Research and development expenses 4,977 4,601 4,927
Acquired in-process research and development expenses 944 939 5,968
In-process research and development impairment 2,700 0 0
Selling, general and administrative expenses 5,673 5,246 5,151
Total costs and expenses 19,951 17,387 20,618
Operating income 7,330 9,918 4,071
Interest expense (935) (1,001) (984)
Other income (expense), net (581) (639) (1,418)
Income before income taxes 5,814 8,278 1,669
Income tax expense (1,248) (2,077) (1,580)
Net income 4,566 6,201 89
Net loss attributable to noncontrolling interest 26 24 34
Net income attributable to Gilead $ 4,592 $ 6,225 $ 123
Basic earnings per share attributable to Gilead (in dollars per share) $ 3.66 $ 4.96 $ 0.10
Shares used in basic earnings per share attributable to Gilead calculation (in shares) 1,255 1,256 1,257
Diluted earnings per share attributable to Gilead (in dollars per share) $ 3.64 $ 4.93 $ 0.10
Shares used in diluted earnings per share attributable to Gilead calculation (in shares) 1,262 1,262 1,263
Product sales      
Revenues:      
Total revenues $ 26,982 $ 27,008 $ 24,355
Royalty, contract and other revenues      
Revenues:      
Total revenues $ 299 $ 297 $ 334